Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021
This review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2022-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2620 |
| _version_ | 1797232091116601344 |
|---|---|
| author | I. S. Yavelov |
| author_facet | I. S. Yavelov |
| author_sort | I. S. Yavelov |
| collection | DOAJ |
| description | This review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented. Large randomized controlled trials EXCLAIM, ADOPT, MAGELLAN, APEX and MARINER with prolonged use of anticoagulants in patients hospitalized with acute nonsurgical diseases before pandemia of COVID-19 are discussed. The first prospective randomized controlled trial MICHELLE with direct oral anticoagulant rivaroxaban in a dose 10 mg once daily after discharge of patients with COVID-19 with high risk at least venous thromboembolism are analyzed. It seems that the most relevant approach for the determination of indications for prolonged use of anticoagulants in doses dedicated for primary prevention of venous thromboembolism after discharge of patients with COVID-19 without apparent indication for anticoagulation is a modified IMPROVE VTE risk score with the addition of elevated in-hospital D-dimer level. And the most well-studied approach for anticoagulation in these patients is a direct peroral anticoagulant rivaroxaban 10 mg once daily for 35 (and possibly up to 45) days after discharge. |
| first_indexed | 2024-03-08T14:00:08Z |
| format | Article |
| id | doaj.art-726095cff4584bc393db8b8ba87a383c |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:54:45Z |
| publishDate | 2022-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-726095cff4584bc393db8b8ba87a383c2024-04-01T07:43:41ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532022-01-0117690891510.20996/1819-6446-2021-12-071963Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021I. S. Yavelov0National Medical Research Center for Therapy and Preventive MedicineThis review discusses reasons for prolonged use of anticoagulants after discharge of patients with COVID-19 without additional indication for anticoagulation. Data regarding rate of thrombotic and thromboembolic complications in patients with COVID-19 after discharge from the hospital are presented. Large randomized controlled trials EXCLAIM, ADOPT, MAGELLAN, APEX and MARINER with prolonged use of anticoagulants in patients hospitalized with acute nonsurgical diseases before pandemia of COVID-19 are discussed. The first prospective randomized controlled trial MICHELLE with direct oral anticoagulant rivaroxaban in a dose 10 mg once daily after discharge of patients with COVID-19 with high risk at least venous thromboembolism are analyzed. It seems that the most relevant approach for the determination of indications for prolonged use of anticoagulants in doses dedicated for primary prevention of venous thromboembolism after discharge of patients with COVID-19 without apparent indication for anticoagulation is a modified IMPROVE VTE risk score with the addition of elevated in-hospital D-dimer level. And the most well-studied approach for anticoagulation in these patients is a direct peroral anticoagulant rivaroxaban 10 mg once daily for 35 (and possibly up to 45) days after discharge.https://www.rpcardio.online/jour/article/view/2620covid-19venous thromboembolismdeep vein thrombosispulmonary embolismpreventionheparinenoxaparindirect oral anticoagulantsrivaroxabanapixabanbetrixaban |
| spellingShingle | I. S. Yavelov Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 Рациональная фармакотерапия в кардиологии covid-19 venous thromboembolism deep vein thrombosis pulmonary embolism prevention heparin enoxaparin direct oral anticoagulants rivaroxaban apixaban betrixaban |
| title | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 |
| title_full | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 |
| title_fullStr | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 |
| title_full_unstemmed | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 |
| title_short | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 |
| title_sort | anticoagulants after discharge in patients with covid 19 what we know at the end of 2021 |
| topic | covid-19 venous thromboembolism deep vein thrombosis pulmonary embolism prevention heparin enoxaparin direct oral anticoagulants rivaroxaban apixaban betrixaban |
| url | https://www.rpcardio.online/jour/article/view/2620 |
| work_keys_str_mv | AT isyavelov anticoagulantsafterdischargeinpatientswithcovid19whatweknowattheendof2021 |